Tumour and patient factors in renal cell carcinoma - Towards personalized therapy

Nature Reviews Urology

Volumn 12, Issue 5, 2015, Pages 253-262

  Haddad, Ahmed Q ^a   Margulis, Vitaly ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR INHIBITOR; SUNITINIB; UNCLASSIFIED DRUG;

CANCER SURVIVAL; COUNSELING; DRUG METABOLISM; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; HUMAN; IMMUNE RESPONSE; KIDNEY CARCINOMA; NONHUMAN; PATIENT CARE; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT; CARCINOMA, RENAL CELL; DISEASE MANAGEMENT; KIDNEY NEOPLASMS; PROCEDURES; PROGNOSIS;

CARCINOMA, RENAL CELL; DISEASE MANAGEMENT; HUMANS; KIDNEY NEOPLASMS; PRECISION MEDICINE; PROGNOSIS;

EID: 84930767254     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2015.71     Document Type: Review

References (134)

1. Joensuu, H. et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J. Clin. Oncol. 27, 5685-5692 (2009).
2. Spielmann, M. et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J. Clin. Oncol. 27, 6129-6134 (2009).
3. Amado, R. G. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 1626-1634 (2008).
4. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
5. Cancer Genome Atlas Research, Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43-49 (2013).
6. Sato, Y. et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat. Genet. 45, 860-867 (2013).
7. Dalgliesh, G. L. et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463, 360-363 (2010).
8. Guo, G. et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat. Genet. 44, 17-19 (2012).
9. Arai, E. et al. Multilayer-omics analysis of renal cell carcinoma, including the whole exome, methylome and transcriptome. Int. J. Cancer 135, 1330-1342 (2014).
10. Scelo, G. L. et al. Variation in genomic landscape of clear cell renal cell carcinoma across Europe. Nat. Commun. 5, 5135 (2014).
11. Davis, C. F. et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 26, 319-330 (2014).
12. Durinck, S. et al. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nat. Genet. 47, 13-21 (2014).
13. Varela, I. et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539-542 (2011).
14. Srigley, J. R. et al. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am. J. Surg. Pathol. 37, 1469-1489 (2013).
15. Kane, C. J. et al. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer 113, 78-83 (2008).
16. Janzen, N. K. et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol. Clin. North Am. 30, 843-852 (2003).
17. Chen, D. Y. & Uzzo, R. G. Evaluation and management of the renal mass. Med. Clin. North Am. 95, 179-189 (2011).
18. Chin, A. I. et al. Surveillance strategies for renal cell carcinoma patients following nephrectomy. Rev. Urol. 8, 1-7 (2006).
19. Karakiewicz, P. I. et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J. Clin. Oncol. 25, 1316-1322 (2007).
20. Zisman, A. et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J. Clin. Oncol. 19, 1649-1657 (2001).
21. Frank, I. et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J. Urol. 168, 2395-2400 (2002).
22. Leibovich, B. C. et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97, 1663-1671 (2003).
23. Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007).
24. Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007).
25. Rini, B. I. et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol. 28, 2137-2143 (2010).
26. Negrier, S. et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol. 12, 673-680 (2011).
27. Sternberg, C. N. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 28, 1061-1068 (2010).
28. Coppin, C. et al. Immunotherapy for advanced renal cell cancer [online], Cochrane Database Syst. Rev. http://dx.doi.org/10.1002/14651858.CD001425.pub2 (2004).
29. Rosenberg, S. A. et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271, 907-913 (1994).
30. Rosenberg, S. A. et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann. Surg. 228, 307-319 (1998).
31. Escudier, B. et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol. 28, 2144-2150 (2010).
32. Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584-3590 (2009).
33. Motzer, R. J. et al. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N. Engl. J. Med. 370, 1769-1770 (2014).
34. Rini, B. I. & Atkins, M. B. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 10, 992-1000 (2009).
35. Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225-233 (2014).
36. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).
37. Latif, F. et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260, 1317-1320 (1993).
38. Nickerson, M. L. et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin. Cancer Res. 14, 4726-4734 (2008).
39. Brugarolas, J. Molecular genetics of clear-cell renal cell carcinoma. J. Clin. Oncol. 32, 1968-1976 (2014).
40. Linehan, W. M., Srinivasan, R. & Schmidt, L. S. The genetic basis of kidney cancer: a metabolic disease. Nat. Rev. Urol. 7, 277-285 (2010).
41. Robinson, C. M. & Ohh, M. The multifaceted von Hippel-Lindau tumour suppressor protein. FEBS Lett. 588, 2704-2711 (2014).
42. Keith, B., Johnson, R. S. & Simon, M. C. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 12, 9-22 (2012).
43. Thoma, C. R. et al. VHL loss causes spindle misorientation and chromosome instability. Nat. Cell Biol. 11, 994-1001 (2009).
44. Kapur, P. et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol. 14, 159-167 (2013).
45. Farley, M. N. et al. A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma. Mol. Cancer Res. 11, 1061-1071 (2013).
46. Wang, S. S. et al. Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis. Proc. Natl Acad. Sci. USA 111, 16538-16543 (2014).
47. Haddad, A. Q. et al. Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma. Cancer 121, 43-50 (2014).
48. Dondeti, V. R. et al. Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets. Cancer Res. 72, 112-121 (2012).
49. Girgis, A. H. et al. Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma. Cancer Res. 72, 5273-5284 (2012).
50. Beroukhim, R. et al. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 69, 4674-4681 (2009).
51. Olshan, A. F. et al. Racial difference in histologic subtype of renal cell carcinoma. Cancer Med. 2,744-749 (2013).
52. Lipworth, L. et al. Renal cell cancer histologic subtype distribution differs by race and sex. BJU Int. http://dx.doi.org/10.1111/bju.12950 (2014).
53. Hoang, M. L. et al. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci. Transl. Med. 5, 197ra102 (2013).
54. Nortier, J. L. et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N. Engl. J. Med. 342, 1686-1692 (2000).
55. Lemy, A. et al. Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. Am. J. Kidney Dis. 51, 471-477 (2008).
56. Modena, P. et al. UQCRH gene encoding mitochondrial Hinge protein is interrupted by a translocation in a soft-tissue sarcoma and epigenetically inactivated in some cancer cell lines. Oncogene 22, 4586-4593 (2003).
57. Hoffman, A. M. & Cairns, P. Epigenetics of kidney cancer and bladder cancer. Epigenomics 3, 19-34 (2011).
58. Glas, A. M. et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 7, 278 (2006).
59. Takahashi, M. et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc. Natl Acad. Sci. USA 98, 9754-9759 (2001).
60. Sanjmyatav, J. et al. A specific gene expression signature characterizes metastatic potential in clear cell renal cell carcinoma. J. Urol. 186, 289-294 (2011).
61. Jones, J. et al. Gene signatures of progression and metastasis in renal cell cancer. Clin. Cancer Res. 11, 5730-5739 (2005).
62. Sultmann, H. et al. Gene expression in kidney cancer is associated with cytogenetic abnormalities, metastasis formation, and patient survival. Clin. Cancer Res. 11, 646-655 (2005).
63. Zhao, H. et al. Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med. 3, e13 (2006).
64. Brannon, A. R. et al. Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes Cancer 1, 152-163 (2010).
65. Brannon, A. R. et al. Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. Eur. Urol. 61, 258-268 (2012).
66. Brooks, S. A. et al. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. Eur. Urol. 66, 77-84 (2014).
67. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
68. Sorlie, T. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100, 8418-8423 (2003).
69. Burrell, R. A. et al. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501, 338-345 (2013).
70. Nowell, P. C. The clonal evolution of tumor cell populations. Science 194, 23-28 (1976).
71. Fisher, R., Pusztai, L. & Swanton, C. Cancer heterogeneity: implications for targeted therapeutics. Br. J. Cancer 108, 479-485 (2013).
72. Campbell, P. J. et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467, 1109-1113 (2010).
73. Hovey, R. M. et al. Genetic alterations in primary bladder cancers and their metastases. Cancer Res. 58, 3555-3560 (1998).
74. Jiang, J. K. et al. Genetic changes and clonality relationship between primary colorectal cancers and their pulmonary metastases-an analysis by comparative genomic hybridization. Genes Chromosomes Cancer 43, 25-36 (2005).
75. Wu, X. et al. Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 482, 529-533 (2012).
76. Shah, S. P. et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461, 809-813 (2009).
77. Gulati, S. et al. Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers. Eur. Urol. 66, 936-948 (2014).
78. Navin, N. et al. Tumour evolution inferred by single-cell sequencing. Nature 472, 90-94 (2011).
79. Wang, Y. et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 512, 155-160 (2014).
80. Xu, X. et al. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 148, 886-895 (2012).
81. Yang, X. J et al. A molecular classification of papillary renal cell carcinoma. Cancer Res. 65, 5628-5637 (2005).
82. Delahunt, B. et al. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum. Pathol. 32, 590-595 (2001).
83. Klatte, T. et al. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin. Cancer Res. 15, 1162-1169 (2009).
84. Kovacs, G. Papillary renal cell carcinoma. A morphologic and cytogenetic study of 11 cases. Am. J. Pathol. 134, 27-34 (1989).
85. Zbar, B. et al. Hereditary papillary renal cell carcinoma. J. Urol. 151, 561-566 (1994).
86. Launonen, V. et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc. Natl Acad. Sci. USA 98, 3387-3392 (2001).
87. Schmidt, L. et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 16, 68-73 (1997).
88. Tomlinson, I. P. et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet. 30, 406-410 (2002).
89. Nickerson, M. L et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2, 157-164 (2002).
90. Klomp, J. A. et al. Birt-Hogg-Dube renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression. BMC Med. Genomics 3, 59 (2010).
91. Schwerdtle, R. F. et al. Allelic losses at chromosomes 1p, 2p, 6p, 10p, 13q, 17p, and 21q significantly correlate with the chromophobe subtype of renal cell carcinoma. Cancer Res. 56, 2927-2930 (1996).
92. Gad, S. et al. Mutations in BHD and TP53 genes, but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma. Br. J. Cancer 96, 336-340 (2007).
93. Rohan, S. et al. Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes. Clin. Cancer Res. 12, 6937-6945 (2006).
94. Junttila, M. R. & de Sauvage, F. J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501, 346-354 (2013).
95. Santoni, M. et al. Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor. Int. J. Cancer 134, 2772-2777 (2014).
96. Purdue, M. P. et al. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat. Genet. 43, 60-65 (2011).
97. Schodel, J. et al. Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression. Nat. Genet. 44, 420-425, S1-2 (2012).
98. Moore, L. E. et al. Apolipoprotein E/C1 locus variants modify renal cell carcinoma risk. Cancer Res. 69, 8001-8008 (2009).
99. Henrion, M. et al. Common variation at 2q22.3 (ZEB2) influences the risk of renal cancer. Hum. Mol. Genet. 22, 825-831 (2013).
100. Wu, X. et al. A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. Hum. Mol. Genet. 21, 456-462 (2012).
101. Audenet, F. et al. Germline genetic variations at 11q13 and 12p11 locus modulate age at onset for renal cell carcinoma J. Urol. 191, 487-492 (2014).
102. Schutz, F. A. et al. Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol. 14, 81-87 (2013).
103. Garcia-Donas, J. et al. Renal carcinoma pharmacogenomics and predictors of response: Steps toward treatment individualization. Urol. Oncol. http://dx.doi.org/10.1016/j.urolonc.2013.09.015 (2014).
104. Ito, N. et al. STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 25, 2785-2791 (2007).
105. van der Veldt, A. A. et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin. Cancer Res. 17, 620-629 (2011).
106. Kim, J. J. et al. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 118, 1946-1954 (2012).
107. Scartozzi, M. et al. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. Br. J. Cancer 108, 1126-1132 (2013).
108. Beuselinck, B. et al. Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. Br. J. Cancer 108, 887-900 (2013).
109. Lambrechts, D. et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol. 13, 724-733 (2012).
110. Motzer, R. J. et al. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. Cancer Chemother. Pharmacol. 74, 739-750 (2014).
111. van Erp, N. P. et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J. Clin. Oncol. 27, 4406-4412 (2009).
112. Garcia-Donas, J. et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol. 12, 1143-1150 (2011).
113. Kim, H. R. et al. Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients. Cancer Chemother. Pharmacol. 72, 825-835 (2013).
114. Bissell, M. J. & Radisky, D. Putting tumours in context. Nat. Rev. Cancer 1, 46-54 (2001).
115. Fyfe, G. et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13, 688-696 (1995).
116. McDermott, D. F. et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 23, 133-141 (2005).
117. Yang, J. C. et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21, 3127-3132 (2003).
118. Naidoo, J., Page, D. B. & Wolchok, J. D. Immune modulation for cancer therapy. Br. J. Cancer 111, 2214-2219 (2014).
119. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
120. Yang, J. C. et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J. Immunother. 30, 825-830 (2007).
121. Finke, J. H. et al. Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics. Cancer J. 19, 353-364 (2013).
122. Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162-174 (2009).
123. Yang, L. et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6, 409-421 (2004).
124. Ko, J. S. et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 15, 2148-2157 (2009).
125. Yuan, H. et al. Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation. Biomed. Pharmacother. 68, 751-756 (2014).
126. Noy, R. & Pollard, J. W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 41, 49-61 (2014).
127. Chanmee, T. et al. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel) 6, 1670-1690 (2014).
128. Li, C. et al. Knockdown of VEGF receptor-1 (VEGFR-1) impairs macrophage infiltration, angiogenesis and growth of clear cell renal cell carcinoma (CRCC). Cancer Biol. Ther. 12, 872-880 (2011).
129. Menke, J. et al. Autocrine CSF-1 and CSF-1 receptor coexpression promotes renal cell carcinoma growth. Cancer Res. 72, 187-200 (2012).
130. Kitagawa, D. et al. Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase. J. Biochem. 151, 47-55 (2012).
131. Lin, J. C. et al. Sorafenib induces autophagy and suppresses activation of human macrophage. Int. Immunopharmacol. 15, 333-339 (2013).
132. Thompson, R. H. et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc. Natl Acad. Sci. USA 101, 17174-17179 (2004).
133. Jilaveanu, L. B. et al. PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases. J. Cancer 5, 166-172 (2014).
134. Bedke, J. et al. Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy. World J. Urol. 32, 31-38 (2014).